Drugs / Darlifarnib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06026410 | Oct 2023 → Jan 2027 expected | clear cell renal carcinoma, colorectal cancer, non-small cell lung carcinoma, pancreatic ductal adenocarcinoma | Kura Oncology, Inc. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 5
| Date | Issuer | Release |
|---|---|---|
| 2026-07-27 | Kura Oncology, Inc. | Results Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026 kuraoncology.com ↗
The long-term data compare favorably with benchmarks for advanced RCC, showing robust antitumor activity with darlifarnib plus cabozantinib, as well as evidence of durable benefit. |
| 2026-06-03 | Kura Oncology, Inc. | Results Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy kuraoncology.com ↗
Preliminary Phase 1a data from darlifarnib + adagrasib demonstrate confirmed, objective response rates of 67% in pancreatic cancer, 50% in non-small cell lung cancer, and 29% in KRAS inhibitor-naïve colorectal cancer patients |
| 2026-05-26 | Kura Oncology, Inc. | Results Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors kuraoncology.com ↗
The combination of darlifarnib plus adagrasib demonstrated meaningful antitumor activity in heavily pretreated pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) patients with prior KRAS inhibitor (KRASi) exposure, as well as KRASi-naïve colorectal cancer (CRC) patients. |
| 2026-04-17 | Kura Oncology, Inc. | Results Kura Oncology Reports Darlifarnib Plus Cabozantinib Demonstrates Robust Activity in Patients With Clear Cell Renal Cell Carcinoma Previously Treated With Cabozantinib kuraoncology.com ↗
In this setting, the combination of darlifarnib and cabozantinib demonstrated robust antitumor activity along with a manageable safety profile as demonstrated in all RCC patients across multiple dose levels, including full dose cabozantinib. |
| 2025-10-18 | Kura Oncology, Inc. | Results Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress kuraoncology.com ↗ |
All press releases naming this drug 7 releases
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Darlifarnib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06026410 ↗ |
| Action | Inhibit | “a farnesyltransferase inhibitor (FTI)” NCT06026410 ↗ |
| Route | Oral | “Oral administration” NCT06026410 ↗ |